AN OPEN-LABEL, 6-MONTH OBSERVATIONAL STUDY OF PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS RECEIVING RISPERIDONE LONG ACTING INJECTION

被引：0
|
作者：
Hustig, Harry [1 ]
Newton, Richard [2 ]
Nyst, Phil [3 ]
机构：
[1] Glenside Hosp, Eastwood, SA, Australia
[2] Frankston Hosp, Frankston, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
来源：
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：A56 / A56
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients
    Verma, Swapna
    Subramaniam, Mythily
    Abdin, Edimansyah
    Sim, Kang
    Su, Alex
    Lee, Nelson
    Chong, Siow Ann
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2010, 25 (03) : 230 - 235
  • [2] Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
    Takekita, Yoshiteru
    Koshikawa, Yosuke
    Fabbri, Chiara
    Sakai, Shiho
    Sunada, Naotaka
    Onohara, Ai
    Nishida, Keiichiro
    Yoshimura, Masafumi
    Kato, Masaki
    Serretti, Alessandro
    Kinoshita, Toshihiko
    BMC PSYCHIATRY, 2016, 16
  • [3] Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
    Yoshiteru Takekita
    Yosuke Koshikawa
    Chiara Fabbri
    Shiho Sakai
    Naotaka Sunada
    Ai Onohara
    Keiichiro Nishida
    Masafumi Yoshimura
    Masaki Kato
    Alessandro Serretti
    Toshihiko Kinoshita
    BMC Psychiatry, 16
  • [4] The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial
    Koshikawa, Yosuke
    Takekita, Yoshiteru
    Kato, Masaki
    Sakai, Shiho
    Onohara, Ai
    Sunada, Naotaka
    Nishida, Keiichiro
    Yoshimura, Masafumi
    Fabbri, Chiara
    Serretti, Alessandro
    Kinoshita, Toshihiko
    NEUROPSYCHOBIOLOGY, 2016, 73 (01) : 35 - 42
  • [5] Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
    Citrome, Leslie
    Weiden, Peter J.
    McEvoy, Joseph P.
    Correll, Christoph U.
    Cucchiaro, Josephine
    Hsu, Jay
    Loebel, Antony
    CNS SPECTRUMS, 2014, 19 (04) : 330 - 339
  • [6] Open-label over effectiveness of long-acting risperidone as maintenance therapy of bipolar and schizoaffective disorders
    Castro-Loli, P.
    Benabarre, A.
    Martinez-Aran, A.
    Sanchez-Moreno, J.
    Salamero, M.
    Murru, A.
    Vieta, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S409 - S409
  • [7] LONG-TERM SAFETY AND TOLERABILITY OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A 6-MONTH, OPEN-LABEL STUDY
    Stahl, Steven M.
    Cucchiaro, Josephine
    Simonelli, D.
    Severs, J.
    Loebel, A.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 322 - 322
  • [8] Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder - Randomised, controlled, open-label study
    Keks, Nicholas A.
    Ingham, Michael
    Khan, Akbar
    Karcher, Keith
    BRITISH JOURNAL OF PSYCHIATRY, 2007, 191 : 131 - 139
  • [9] A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
    Findling, Robert L.
    Robb, Adelaide S.
    DelBello, Melissa P.
    Huss, Michael
    McNamara, Nora K.
    Sarkis, Elias H.
    Scheffer, Russell E.
    Poulsen, Lis H.
    Chen, Grace
    Lemming, Ole M.
    Auby, Philippe
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2018, 28 (01) : 47 - 54
  • [10] A 6-month, open-label study of memantine in patients with frontotemporal dementia
    Diehl-Schmid, Janine
    Foerstl, Hans
    Perneczky, Robert
    Pohl, Corina
    Kurz, Alexander
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (07) : 754 - 759
12345